The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use

Frontiers in Pharmacology
Ismaeel Yunusa, Marie Line El Helou

Abstract

Dementia represents a global health challenge due to the increase in elderly population worldwide. In addition to memory loss, dementia often results in severe behavioral and psychological changes where pharmacological treatments might be considered in addition to nonpharmacological strategies for optimal symptomatic control. Risperidone, the second oldest atypical antipsychotic, has been widely used off-label to treat behavioral and psychological symptoms of dementia (BPSD), including agitation, aggression, and psychosis. Several studies have indicated that risperidone offers a modest and statistically significant effectiveness in the clinical setting. However, in the past decade, safety concerns emerged due to increased risk for cerebrovascular adverse events and death following the use of risperidone in the elderly population. Clinical guidelines suggest that, in severe dementia where an older adult is threatening to harm himself or others, pharmacological treatments might be considered when nonpharmacological treatments fail. Risperidone was approved for BPSD in some countries (Australia, Canada, United Kingdom and New Zealand) but not in the United States. This article reviews risperidone's pharmacological activity, clinic...Continue Reading

References

Jan 29, 2000·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·S WoodJ F Schnelle
Mar 16, 2001·Expert Opinion on Pharmacotherapy·R C Love, M W Nelson
Feb 9, 2005·CNS Drugs·Nathan Herrmann, Krista L Lanctôt
Oct 20, 2005·JAMA : the Journal of the American Medical Association·Lon S SchneiderPhilip Insel
Mar 1, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Lon S SchneiderPhilip S Insel
Sep 10, 2008·Expert Opinion on Pharmacotherapy·Karleen M McNealJacob Mintzer
Mar 24, 2009·Current Neuropharmacology·Rosa LiperotiAndrea Corsonello
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Philip E LeePaula Rochon
Sep 3, 2009·Psychiatric Services : a Journal of the American Psychiatric Association·Douglas L LeslieRobert A Rosenheck
Sep 21, 2010·TheScientificWorldJournal·Nanna H JensenFlorence Sotty
Sep 29, 2011·JAMA : the Journal of the American Medical Association·Alicia Ruelaz MaherPaul G Shekelle
Mar 4, 2015·BMJ : British Medical Journal·Helen C KalesConstantine G Lyketsos
Sep 2, 2016·Therapeutic Advances in Chronic Disease·Rajesh R TampiShilpa Srinivasan
Jan 24, 2017·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Martin R Farlow, Tatyana A Shamliyan
Feb 18, 2017·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Julia KirkhamDallas Seitz
Jul 25, 2017·Lancet·Gill LivingstonNaaheed Mukadam
Sep 5, 2017·Annals of Neurosciences·Sereen Rose ThomsonSaurabh Agarwal
Apr 27, 2018·ACS Chemical Neuroscience·Trevor C Chopko, Craig W Lindsley
May 3, 2019·Australian Prescriber·Stephen R Duma, Victor Sc Fung
Jun 25, 2019·Current Treatment Options in Neurology·John M Ringman, Lon Schneider
Jul 3, 2019·Current Psychiatry Reports·Laurel J Bessey, Art Walaszek
Jan 11, 2020·Frontiers in Pharmacology·Valeria CalsolaroFabio Monzani

❮ Previous
Next ❯

Citations

Dec 15, 2020·Current Opinion in Anaesthesiology·Thomas DuningDaniel Oswald
Dec 9, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Laura SbârceaIonuț Ledeți
Apr 4, 2021·Pharmaceuticals·Valeria CalsolaroFabio Monzani
Apr 4, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Laura SbârceaIonuț Ledeți
Oct 12, 2021·Current Opinion in Pharmacology·Damiana ScuteriGiacinto Bagetta

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Clinical Trials Mentioned

NCT03325556

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here